Citi on Bristol-Myers Squibb Co. (BMY): 'ASCO 2025: Early stage ADCs support breadth of oncology portfolio'
Tweet Send to a Friend
Citi analyst Geoff Meacham reiterated a Neutral rating and $51.00 price target on Bristol-Myers Squibb Co. (NYSE: BMY).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
